Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
19.03
+0.30 (1.60%)
At close: Dec 20, 2024, 4:00 PM
19.20
+0.17 (0.89%)
After-hours: Dec 20, 2024, 4:20 PM EST
Viridian Therapeutics Employees
Viridian Therapeutics had 94 employees as of December 31, 2023. The number of employees increased by 8 or 9.30% compared to the previous year.
Employees
94
Change (1Y)
8
Growth (1Y)
9.30%
Revenue / Employee
$3,213
Profits / Employee
-$2,734,936
Market Cap
1.51B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Teladoc Health | 5,600 |
Evotec SE | 5,061 |
Phreesia | 1,438 |
AtriCure | 1,200 |
Indivior | 1,164 |
Clover Health Investments | 552 |
BioCryst Pharmaceuticals | 536 |
Travere Therapeutics | 380 |
VRDN News
- 2 days ago - Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade) - Seeking Alpha
- 3 days ago - Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation - Seeking Alpha
- 4 days ago - Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade) - Seeking Alpha
- 5 days ago - Viridian Therapeutics' eye disorder drug meets late-stage study goal - Reuters
- 5 days ago - Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease - Business Wire
- 8 days ago - Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024 - Business Wire
- 17 days ago - Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data - Business Wire